Three Australian companies will be presenting at Sharecafe’s “Sip & Learn” webinar today—Nico Resources, Immutep, and Alterity Therapeutics. They focus on mineral exploration, cancer treatment research and neurodegenerative disease drug development. Please register here for your FREE spot.
Alterity Therapeutics: Investigating treatments for brain disorders
Alterity Therapeutics (ASX: ATH) is developing drugs for neurodegenerative diseases, conditions that lead to the gradual loss of brain function. Its main focus is on Multiple System Atrophy (MSA), a rare disease that affects movement and bodily functions.
The company’s leading drug candidate, ATH434, is designed to slow down the buildup of a protein called alpha-synuclein, which is linked to MSA and other neurological disorders. The drug is in the early stages of clinical trials, meaning it is being tested for safety and effectiveness in humans.
Nico Resources: Developing a nickel and cobalt resource
Nico Resources (ASX: NC1) is a mining company working to develop the Wingellina Nickel-Cobalt Project in Western Australia. This project is part of a larger mining region known as the Central Musgrave Project, which extends across Western Australia, the Northern Territory, and South Australia.
The company’s goal is to extract and refine nickel and cobalt, which are used in battery production, particularly for electric vehicles. The site contains an estimated two million tonnes of nickel and 154,000 tonnes of cobalt, making it one of the larger undeveloped nickel deposits in Australia.
Immutep: Researching cancer and autoimmune treatments
Immutep (ASX: IMM, NASDAQ: IMMP) is a biotechnology company that develops drugs designed to help the body’s immune system fight cancer and autoimmune diseases. Its main drug in development is eftilagimod alpha (IMP321), which aims to strengthen the immune system’s ability to detect and attack cancer cells.
The drug works by targeting a protein called LAG-3, which plays a role in controlling immune system responses. Immutep is testing whether this treatment can improve outcomes when combined with existing cancer drugs. The company is conducting clinical trials, which are required before a drug can be approved for general use.
Immutep also has other research projects focused on autoimmune diseases, conditions where the body’s immune system mistakenly attacks its own cells.
